title: Lusutrombopag: First Global Approval.
abstract: Lusutrombopag (Mulpleta®) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels. In September 2015, lusutrombopag received its first global approval in Japan for the improvement of CLD-associated thrombocytopenia in patients scheduled to undergo elective invasive procedures. This article summarizes the milestones in the development of lusutrombopag leading to this first approval.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand. dru@adis.com.
authors.forename: Esther S
authors.initials: ES
authors.lastname: Kim
mesh_terms: D002934:Cinnamates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D007564:Japan; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D013844:Thiazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000150:complications / Q000188:drug therapy*
chemical_list: D002934:Cinnamates; D053628:Receptors, Thrombopoietin; D013844:Thiazoles; C000611387:lusutrombopag